Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GMED 
Globus Medical (GMED)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: GMED (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $79.6
1 Year Target Price $79.6
| 4 | Strong Buy |
| 5 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.34% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.91B USD | Price to earnings Ratio 23.09 | 1Y Target Price 79.6 |
Price to earnings Ratio 23.09 | 1Y Target Price 79.6 | ||
Volume (30-day avg) 14 | Beta 1.12 | 52 Weeks Range 51.79 - 94.93 | Updated Date 10/17/2025 |
52 Weeks Range 51.79 - 94.93 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.58% | Operating Margin (TTM) 17.33% |
Management Effectiveness
Return on Assets (TTM) 5.82% | Return on Equity (TTM) 8.62% |
Valuation
Trailing PE 23.09 | Forward PE 15.82 | Enterprise Value 7733081760 | Price to Sales(TTM) 3.01 |
Enterprise Value 7733081760 | Price to Sales(TTM) 3.01 | ||
Enterprise Value to Revenue 2.94 | Enterprise Value to EBITDA 12.47 | Shares Outstanding 112627150 | Shares Floating 111739613 |
Shares Outstanding 112627150 | Shares Floating 111739613 | ||
Percent Insiders 0.68 | Percent Institutions 103.46 |
Upturn AI SWOT
Globus Medical
Company Overview
History and Background
Globus Medical was founded in 2003 and is headquartered in Audubon, Pennsylvania. The company focuses on designing, developing, and commercializing musculoskeletal implants. Significant milestones include developing the first robotic navigation system, ExcelsiusGPS, for spinal surgery.
Core Business Areas
- Spine: Focuses on developing and commercializing a comprehensive portfolio of spinal implants, including thoracolumbar, cervical, and interbody fusion devices.
- Trauma: Includes a range of implants and instruments for the treatment of fractures and other traumatic injuries of the extremities and pelvis.
- Enabling Technologies: Globus Medical offers technologies to improve surgical outcomes and efficiency including ExcelsiusGPS and imaging/navigation systems.
Leadership and Structure
David Paul is the Chairman and CEO. The company has a traditional hierarchical structure with departments like R&D, Sales, Marketing, Operations, and Finance reporting to executive leadership.
Top Products and Market Share
Key Offerings
- Market Share (%):
- Spinal Implants: Globus Medical's spinal implants form a significant portion of revenue, but the exact market share data for individual implants is not readily available. Competitors include Medtronic (MDT), Johnson & Johnson (JNJ, DePuy Synthes), and Stryker (SYK).
- ExcelsiusGPS: This robotic navigation platform assists surgeons during spinal procedures. It provides real-time visualization and precise instrument placement. Competitors include Medtronic's Mazor X Stealth Edition and Stryker's Mako System.
- Market Share (%):
- Market Share (%):
- Trauma Implants: A range of plates, screws, and other implants used in the treatment of orthopedic fractures. Major competitors in this segment include Zimmer Biomet (ZBH), and DePuy Synthes (JNJ).
Market Dynamics
Industry Overview
The musculoskeletal implant market is driven by an aging population, increasing prevalence of spinal disorders, and advancements in surgical techniques. It is highly competitive and regulated.
Positioning
Globus Medical is positioned as a technology innovator, particularly with its robotic surgery platform. Its competitive advantage lies in its vertically integrated manufacturing process and a focus on surgical innovation. The acquisition of Nuvasive further consolidates its market position.
Total Addressable Market (TAM)
The global spine and orthopedics market is estimated to be over $50 billion. Globus Medical is positioned to expand its market share in spinal implants, robotics and trauma within this TAM.
Upturn SWOT Analysis
Strengths
- Strong product portfolio
- Innovative technology (ExcelsiusGPS)
- Vertically integrated manufacturing
- Strong sales force and distribution network
- Acquisition of Nuvasive.
Weaknesses
- Reliance on spinal implant market
- High R&D expenses
- Potential pricing pressure in the competitive market.
- Integration risk with Nuvasive acquisition.
Opportunities
- Expansion into emerging markets
- Development of new robotic surgery applications
- Increased adoption of minimally invasive surgery
- Expanding into new segments through organic growth and strategic acquisitions.
Threats
- Intense competition from larger players
- Regulatory changes and compliance requirements
- Product liability risks
- Reimbursement pressures from healthcare providers.
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Johnson & Johnson (JNJ)
- Stryker (SYK)
- Zimmer Biomet (ZBH)
Competitive Landscape
Globus Medical's advantages include its innovative technology and vertically integrated manufacturing. Disadvantages include its smaller size compared to larger competitors and its reliance on the spinal implant market.
Major Acquisitions
Nuvasive
- Year: 2023
- Acquisition Price (USD millions): 3000
- Strategic Rationale: The acquisition of Nuvasive expands Globus Medical's product portfolio and strengthens its position in the spine market.
Growth Trajectory and Initiatives
Historical Growth: Globus Medical has historically demonstrated solid revenue growth driven by new product launches and market share gains.
Future Projections: Analyst estimates project continued revenue growth driven by increased adoption of robotic surgery and expansion into new markets. Project profitability to be stable or increasing.
Recent Initiatives: Recent initiatives include expanding the ExcelsiusGPS platform, launching new spinal implants, and strategic acquisitions such as Nuvasive. Increased focus on enabling technology.
Summary
Globus Medical is a strong player in the musculoskeletal implant market, known for its innovative technology and vertically integrated manufacturing. The company's robotic surgery platform, ExcelsiusGPS, provides a significant competitive advantage. However, it faces stiff competition from larger companies and needs to diversify its product offerings beyond spinal implants. The acquisition of Nuvasive strengthens its portfolio but integration is key.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is based on publicly available estimates and may not be precise. Financial data should be verified with the company's official filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Globus Medical
Exchange NYSE | Headquaters Audubon, PA, United States | ||
IPO Launch date 2012-08-03 | CEO, President & Director Mr. Keith W. Pfeil | ||
Sector Healthcare | Industry Medical Devices | Full time employees 5300 | Website https://www.globusmedical.com |
Full time employees 5300 | Website https://www.globusmedical.com | ||
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.